Proto-Oncogene Proteins - Metabolism
Research News and Information

Monday, November 23, 2009

The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms.

13 Nov 2009 The spectrum of tumors showing microsatellite instability (MSI) has recently been enlarged to sporadic neoplasms whose incidence is favored in the context of chronic immunosuppression. We investigated the biological, therapeutic and clinical ... Read more...

Necdin: a multi functional protein with potential tumor suppressor role?

30 Oct 2009 Necdin (NDN), a member of the melanoma-associated antigen (MAGE) family of proteins was first identified in mouse stem cells of embryonal carcinoma origin induced to differentiate by treatment with retinoic acid. The human gene maps to chromosome ... Read more...

IRAK1-independent pathways required for the interleukin-1-stimulated activation of the Tpl2 catalytic subunit and its dissociation from ABIN2.

21 Oct 2009 The protein kinase Tpl2 (tumour progression locus 2) is activated by LPS (lipopolysaccharide), TNFalpha (tumour necrosis factor alpha) and IL (interleukin)-1. Activation of the native Tpl2 complex by these agonists requires the IKKbeta {IkappaB ... Read more...

Latest indexed articles for 'Proto-Oncogene Proteins - Metabolism'

These are the very latest articles for this heading:

• The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. 13 Nov 2009
• Necdin: a multi functional protein with potential tumor suppressor role? 30 Oct 2009
• IRAK1-independent pathways required for the interleukin-1-stimulated activation of the Tpl2 catalytic subunit and its dissociation from ABIN2. 21 Oct 2009
• PU.1 regulates TCR expression by modulating GATA-3 activity. 13 Oct 2009
• RAS and CSF3R mutations in severe congenital neutropenia. 13 Oct 2009
• A recurrent network involving the transcription factors PU.1 and Gfi1 orchestrates innate and adaptive immune cell fates. 6 Oct 2009
• CCM2 and CCM3 proteins contribute to vasculogenesis and angiogenesis in human placenta. 29 Sep 2009
• Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. 29 Sep 2009
• Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein. 29 Sep 2009
• The role of CBFbeta in AML1-ETO's activity. 22 Sep 2009
• Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. 12 Sep 2009
• Live or let die: CCM2 provides the link. 8 Sep 2009
• Lipocalin 2 regulation by thermal stresses: protective role of Lcn2/NGAL against cold and heat stresses. 31 Aug 2009
• Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1. 30 Aug 2009
• Lymphoid lineage fate decision of hematopoietic stem cells. 30 Aug 2009
• Radiofrequency radiation and gene/protein expression: a review. 30 Aug 2009
• Involvement of the mitochondrial pathway in p53-independent apoptosis induced by p28GANK knockdown in Hep3B cells. 29 Aug 2009
• Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional repression. 25 Aug 2009
• Negative action of hepatocyte growth factor/c-Met system on angiotensin II signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. 25 Aug 2009
• Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin. 23 Aug 2009

See a longer list of these articles.

Technical information about 'Proto-Oncogene Proteins'

Definition: Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.

Registry Number: 0

Descriptor UI: D011518

Alternative terms: Proto-Oncogene Proteins; Proto Oncogene Proteins; Proto-Oncogene Products, Cellular; Cellular Proto-Oncogene Products; Proto Oncogene Products, Cellular; Proto Oncogene Proteins, Cellular; c-onc Proteins; c onc Proteins; Cellular Proto-Oncogene Proteins; Cellular Proto Oncogene Proteins; Proto-Oncogene Proteins, Cellular;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.776.624.664.700;

Online Note: use PROTO-ONCOGENE PROTEINS to search PROTO-ONCOGENE PROTEINS, CELLULAR 1986-90

History Note: 91; was PROTO-ONCOGENE PROTEINS, CELLULAR 1986-90

Technical Notes: GEN or unspecified; prefer specifics; /drug eff /ultrastruct permitted; DF: note short X ref